Fabtech Technologies was incorporated under the Companies Act, 2013 as a private limited company under the name and style of ‘Globeroute Ventures Private Limited’ pursuant a certificate of incorporation dated October 26, 2018 issued by the Registrar of Companies, Central Registration Centre.

Fabtech Technologies is a global company headquartered in India, specializing in turnkey engineering solutions for pharmaceuticals, biotech and healthcare companies. The company has presence across some of the key emerging economies like Bangladesh, Egypt, Ethiopia, India, Kenya, Kingdom of Saudi Arabia, Morocco, Nicaragua, Nigeria, South Africa, Turkey, UAE, USA and Tanzania. It provides extensive technical expertise and infrastructure to deliver comprehensive solutions for establishing aseptic manufacturing facilities, encompassing everything from design to certification. It offers comprehensive start to finish services in greenfield projects, encompassing disease identification, planning, designing, engineering, procurement, quality assurance, logistics management and installation and commissioning for a wide range of customers across various geographies, particularly key emerging economies.

Additionally, it also offers some of its engineering solutions, which majorly include, equipment procurement and supply and logistics management, on a standalone basis, either as part of greenfield or brownfield projects. In such projects, the feasibility study, design and engineering and other execution functions are undertaken by third party solution providers, and its scope is limited to equipment supply or any other services, required by its customers.

Its comprehensive solutions encompass the entire project lifecycle of its customers and address the three key elements in pharmaceuticals, biotech and healthcare facilities, namely, bio clean air, clean water, and process. In addition to offering targeted solutions across the value chain, it also has an established track record in executing pharmaceutical projects across a diverse range of dosage forms, encompassing, liquids, solids, and semisolids. Its turnkey engineering solutions involve an extensive range of services, viz., comprehensive market analysis that combines geographic and demographic insights to understand the current and future competitive environment, disease profiling for aligning solutions to the specific needs of the target market, designing and detailed engineering of equipment tailored to the manufacturing process and the applicable quality standards, leveraging the best technologies to enhance the efficiency, reliability, and sustainability of the projects and execution and commissioning strategy.

Business area of the company

The company is a key turnkey engineering solution provider in pharmaceuticals capex space, offering comprehensive start to finish solutions encompassing designing, engineering, procurement, installation and testing of pharmaceutical equipment for a wide range of customers. It offers services in greenfield projects for a wide range of customers primarily in the pharmaceutical, healthcare and biotech sector across various geographies, particularly key emerging economies.

Key awards, accreditations or recognitions

• 2017: Fabtech Technologies International Private Limited (formerly known as Fabtech Technologies International Limited) received a token of appreciation from Bangladesh Milk Producers’ Co-operative Union Limited.
• 2017: Fabtech Technologies International Private Limited (formerly known as Fabtech Technologies International Limited) received the title of ‘Brand of the Year, 2017’ in recognition for excellence in pharmaceutical and biotechnology by the CEO Magazine.
• 2021: The company received the Tech Leadership Award in the category of Best in future of women’s advancement from Kami Kaze.
• 2022: Certificate issued by UQSR Global Private Limited declaring that it had assessed the occupational health & safety systems of the company and had found it to be in conformity with ISO 45001:2018. The scope of activities covered under the certificate were start to finish (turnkey including tech transfer) engineering solution for pharmaceutical, biotech and healthcare industry.
• 2022: Certificate issued by UQSR Global Private Limited declaring that it had assessed the quality management systems of the Company and had found it to be in conformity with ISO 9001:2015. The scope of activities covered under the certificate were start to finish (turnkey including tech transfer) engineering solution for pharmaceutical, biotech and healthcare industry.
• 2022: Certificate issued by UQSR Global Private Limited declaring that it had assessed the environmental management systems of the company and had found it to be in conformity with ISO 14001:2015. The scope of activities covered under the certificate were start to finish (turnkey including tech transfer) engineering solution for pharmaceutical, biotech and healthcare industry.
• 2024: Accorded the status of two-star export house under the provisions of Foreign Trade Policy, 2023 by the Directorate General of Foreign Trade, Department of Commerce and Ministry of Commerce and Industry.
• 2025: Received a letter of gratitude from the Akshaya Patra Foundation acknowledging its contribution under the PM POSHAN programme.

History and milestones

• 2020: Pursuant to the Scheme of Amalgamation, the export division of FTIPL, under which it executed turnkey pharmaceutical engineering projects, was transferred to its Company. Further, pursuant to the Scheme of Arrangement, its entire shareholding was transferred from FTIPL to the shareholders of FTIPL, by virtue of which, Aasif Ahsan Khan, Hemant Mohan Anavkar Aarif Ahsan Khan and Manisha Hemant Anavkar became the Promoters of the company.
• 2020: Crossed Rs 10,000 lakh revenue mark in Financial Year 2019-20.
• 2022: Successfully completed a turnkey project for a state-owned organization in Bangladesh, involving installation of 172 clean room doors across designated buildings, as outlined in the project tender.
• 2022: Crossed Rs 25,000 lakh revenue mark in Financial Year 2021-2022.
• 2023: Successfully completed supply and installation of process equipment, such as isolators, tablet compression equipment, and related infrastructure of an aggregate value of Rs 315.94 lakh for a pharmaceutical manufacturer in Algeria.
• 2023: Successfully completed procurement, implementation of facilities and monitoring of cleanrooms installation work for a facility to manufacture oral solid dosage, liquid oral dosage, disinfectant and penicillin secondary packaging area in Kingdom of Saudi Arabia.
• 2023-2024: Acquired FT Institutions Private Limited from FTIPL to create a domestic presence and robust government clientele by executing turnkey pharmaceutical engineering projects in India.
• 2023-2024: With an intent to create a local presence in the Middle Eastern region, set up a wholly-owned subsidiary, Fabtech Technologies LLC and a step-down subsidiary, FTS Cleanrooms Systems LLC in Sharjah, United Arab Emirates.
• 2024: Acquired FABL International Technologies LLP from FTIPL to integrate its operations by developing manufacturing capabilities in oral solid dosage process solutions through its Subsidiary.
• 2024: Acquisition of a controlling interest of 51% in its erstwhile associate company, TSA Process Equipments Private Limited by Thermax Limited.
• 2024: Pursuant to a business transfer agreement dated May 1, 2024, its Step-Down Subsidiary, FTS Cleanrooms Systems LLC acquired certain identified assets and liabilities, third-party contracts, licenses, ongoing projects, employees, vendors and other agencies of FTS Lifecare Technical Services LLC.
• 2025: Acquired 33.33% stake in Mark Maker Engineering Private Limited, for geographical expansion and operational synergies, thereby making it an associate of the Company.